Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2025-02-06 Investor Presentation
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Please find attached the investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation - Q3’ FY25' and is addressed to stock exchanges with a subject line explicitly stating it is an investor presentation. The content includes detailed financial performance data for the quarter and nine months ended December 31, 2024, including revenue, EBITDA, profit before tax, and earnings per share. It also contains forward-looking statements, disclaimers, and segment-wise business performance analysis typical of investor presentations. The document length is about 15,000 characters, which is consistent with a detailed presentation rather than a brief announcement. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The presence of detailed financial and operational data aimed at investors confirms it is an Investor Presentation.
2025-02-06 English
Please find attached the file
Regulatory Filings
2025-02-06 English
Financial Result Updates
Regulatory Filings
2025-02-06 English
Please find attached results and LLR - Q3 FY 25
Regulatory Filings
2025-02-06 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-02-03 English
Please find enclosed intimation of post results (Q-3 FY 25) investors/ analyst conference call scheduled on Thursday, February 06, 2025 at 3.30 p.m. (IST).
Call Transcript Classification · 90% confidence The document is a notification to stock exchanges about an upcoming conference call to discuss the company's Q3 FY25 financial results. It references the declaration of unaudited financial results for the quarter and nine months ended December 31, 2024, and provides details about the date, time, and participants of the call. The document does not contain the financial results themselves, nor detailed financial statements or analysis. It is an announcement of a conference call related to earnings results, not the earnings release or the call transcript itself. Therefore, the document fits best as a Call Transcript (CT) precursor or announcement, but since it is specifically about the scheduling and details of the conference call, it is best classified as a Call Transcript (CT) type document, as it is directly related to the earnings call event. Confidence is high because the document explicitly states it is about the conference call for Q3 FY25 results and includes call details and participants, which is typical for a Call Transcript or related document.
2025-02-03 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.